Investing.com -- Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it noted uncertainty around the company’s near-term growth prospects despite long-term value potential.
Biogen has traded between $200 and $350 over the past decade, offering volatility for hedge funds but limited sustained value for long-term investors, Bernstein said in a note. The company’s fortunes have largely been tied to Alzheimer’s treatments, but the launch of Leqembi has underwhelmed expectations, with peak sales estimates cut by 40% in 2024.
Bernstein believes Biogen is undervalued at less than 10 times price-to-earnings but sees no urgency to buy, noting that an inflection in the stock’s narrative is unlikely before 2026. The firm also flagged potential risks, including competition from semaglutide in Alzheimer’s and possible delays in Leqembi’s subcutaneous induction approval.
Despite its cautious stance, Bernstein credited CEO Chris Viehbacher for implementing a $1 billion cost-cutting plan and making strategic acquisitions, including Reata Pharmaceuticals (NASDAQ:RETA) for $7 billion. It sees Skyclaris reaching $1.6 billion in peak sales, while Biogen’s early pipeline remains underappreciated.
Related Articles
Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty
Rosneft halts Saratov refinery operations due to Ukrainian drone strikes
EU, Canada and Mexico condemn Trump move to hike steel and aluminium tariffs
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。